Market Cap : 218.92 M | Enterprise Value : 130.1 M | PE Ratio : At Loss | PB Ratio : 2.75 |
---|
NAS:VTGN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:VTGN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
VistaGen Therapeutics's Short-Term Debt for the quarter that ended in Dec. 2021 was $0.00 Mil.
VistaGen Therapeutics's annual Short-Term Debt stayed the same from Mar. 2019 ($0.06 Mil) to Mar. 2020 ($0.06 Mil) but then declined from Mar. 2020 ($0.06 Mil) to Mar. 2021 ($0.00 Mil).
The historical data trend for VistaGen Therapeutics's Short-Term Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.
Thank you for viewing the detailed overview of VistaGen Therapeutics's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.
Saxe Jon S | director | FIRST HORIZON PHARMACEUTICAL CORP 660 HEMBREE PKWY STE 106 ROSWELL GA 30076 |
Dotson Jerrold Duane | officer: VP, CFO AND SECRETARY | 5 CENTERPOINTE DRIVE SUITE 400 LAKE OSWEGO OR 97035 |
Singh Shawn | director, officer: CHIEF EXECUTIVE OFFICER | C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 |
Snodgrass H. Ralph | director, officer: PRES./CHIEF SCIENTIFIC OFFICER | 384 OYSTER POINT BLVD. SUITE 8 SOUTH SAN FRANCISCO CA 94080 |
Smith Mark Alan | officer: CHIEF MEDICAL OFFICER | 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 |
Mcpartland Mark A. | officer: VP CORPORATE DEVELOPMENT | C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 |
Gin Jerry B | director | 343 ALLERTON AVE SOUTH SAN FRANCISCO CA 94080 |
Underdown Brian J. | director | C/O LUMIRA CAPITAL INVESTMENT MANAGEMENT 141 ADELAIDE ST. WEST, SUITE 770 TORONTO ONTARIO CANADA M5H 3L5 A6 00000 |
Cunningham Ann Michelle | director | 255 N CALDWELL CIRCLE DOWNINGTOWN PA 19335 |
Rice A. Franklin | officer: VP CORPORATE DEVELOPMENT | 384 OYSTER POINT BLVD. SUITE 8 SOUTH SAN FRANCISCO CA 94080 |
Bonfiglio Gregory A. | director | 384 OYSTER POINT BOULEVARD, NO. 8 SOUTH SAN FRANCISCO CA 94080 |
Platinum Long Term Growth Vii, Llc | 10 percent owner | 152 WEST 57TH STREET 4TH FLOOR NEW YORK NY 10019 |
Cato Holding Co | 10 percent owner | 4364 SOUTH ALSTON AVENUE DURHAM NC 27713 |
Cato Allen Easley | 10 percent owner | 4364 SOUTH ALSTON AVENUE DURHAM NC 27713 |
Jones Stephanie | director, 10 percent owner, officer: PRESIDENT | 13834 W. HOYT ROAD RATHDRUM ID 83858 |
From GuruFocus
Other Sources
By Zacks 2021-10-20
By Zacks 2022-02-10
By Zacks 2021-02-11
By Zacks 2021-11-10
By tipranks.com 2022-03-03
By Seekingalpha 2022-02-10
By Seekingalpha 2021-06-29
By Zacks 2021-03-11
By Fool 2021-06-30
By Seekingalpha 2021-01-24
By tipranks.com 2022-02-13
By Zacks 2021-08-12
By Zacks 2021-06-16